Sponsored Content

HER2+ mBC: DESTINY-Breast04 Trial

December 25, 2019

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

Choosing Sides: Treatment Decisions for Recurrent Ovarian Cancer Must Consider Side Effects

May 30, 2019

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.